ArticleFunctional & integrative genomics2026
Whole-genome sequencing and comparative genomics reveal antimicrobial potential and adaptive traits of Bacillus velezensis AM12.
Article in Functional & integrative genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biodegradation Characteristics of Piperacillin by Marine Bacillus cereus PP1 and Genome-Guided Mining of Candidate β-Lactamases.Functional & integrative genomics · 2026Article
- Integrated morpho-biochemical, molecular, phylogenetic, and thermodynamic characterization of Bacillus isolates from ecologically distinct Indian soils.Molecular biology reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The global rise of antimicrobial resistance has intensified the demand for novel antimicrobial agents with broad-spectrum efficacy and unique mechanisms of action. Herein, a marine-derived strain, Bacillus velezensis (B. velezensis) AM12, exhibiting clear inhibitory activity against eight major foodborne pathogens, was isolated from coastal seawater near Zhanjiang, China. Whole-genome sequencing revealed a 3,992,266 bp circular chromosome with a GC content of 46%, and functional annotation indicated extensive metabolic potential. Genome mining using the antiSMASH platform identified 14 secondary metabolite biosynthetic gene clusters, including those encoding surfactin, macrolactin H, bacillaene, fengycin, difficidin, bacillibactin, and bacilysin, as well as several additional clusters potentially responsible for the biosynthesis of novel antimicrobial compounds. Analysis using the BAGEL4 database further detected four bacteriocin/RiPP biosynthetic loci, corresponding to Competence/ComX, Amylocyclicin, LCI, and a Lichenicidin-like cluster. These collectively explain the broad-spectrum antibacterial activity of AM12 and suggest potential antifungal capability. Notably, the core genes of ComX and LCI exhibited relatively low similarity (46.67% and 73.91%, respectively) to known references, and B. velezensis AM12-origin lichenicidin component 2 showed no detectable homology, suggesting that AM12 may encode structurally and functionally distinct novel bacteriocins. Comparative genomic analysis with closely related terrestrial B. velezensis strains revealed that AM12-specific genes are predominantly enriched in functions associated with marine environmental adaptation and antimicrobial activity. Furthermore, machine learning-based prediction using the AM12-specific gene set identified seven high-confidence antimicrobial peptide candidates characterized by cationic charge, amphipathicity, and structural stability. This study elucidates the genomic and molecular basis of the broad-spectrum antibacterial activity pertaining to B. velezensis AM12, and establishes a systematic framework for the identification of novel antimicrobial peptides, offering candidate genes for subsequent functional characterization.
Indexed as
Identifiers
41546830What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.